Scanfil Oyj
4.3.2021 11:31:38 CET | Globenewswire | Press release
SCANFIL PLC MANAGERS' TRANSACTIONS 4 March 2021 12.30 P.M.
Scanfil plc: Managers' transactions
Person subject to the notification requirement
Name: Valo Kai
Position: Chief Financial Officer
Issuer: Scanfil Oyj
LEI: 7437004XD6U0FFDCT507
Notification type: INITIAL NOTIFICATION
Reference number: 7437004XD6U0FFDCT507_20210303115909_3
____________________________________________
Transaction date: 2021-03-03
Venue not applicable
Instrument type: SHARE
ISIN: FI4000029905
Nature of the transaction: SUBSCRIPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 10,000 Unit price: 3.57 EUR
Aggregated transactions
(1): Volume: 10,000 Volume weighted average price: 3.57 EUR
SCANFIL PLC
Petteri Jokitalo
CEO
For additional information:
CEO Petteri Jokitalo
tel. +358 8 4882 111
www.scanfil.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Fast Ejendom Danmark29.3.2026 18:17:55 CEST | Pressemeddelelse
Aktietilbagekøbsprogram
Newcap Holdings29.3.2026 12:19:20 CEST | Pressemeddelelse
NewCap Holding A/S har indgået en aftale, betinget af underskrivelse af endelige aftaledokumenter m.v., om erhvervelse af dansk selskab indenfor compliance og risikostyringsservices – Intern viden
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom